Vertex Pharma (VRTX) Tops Q3 EPS by 48c, Lifts FY Guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $510.72 +0.47%
Revenue Growth %: +10.7%
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +10.7%
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $3.56, $0.48 better than the analyst estimate of $3.08. Revenue for the quarter came in at $1.98 billion versus the consensus estimate of $1.86 billion.
GUIDANCE:
Vertex Pharma sees FY2021 revenue of $7.4-7.5 billion, versus the consensus of $7.32 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold
- Jefferies Starts DBS Group Holdings (DBS:SP) (DBSDY) at Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
